United Therapeutics Corporation Equity Method Investment, Realized Gain (Loss) on Disposal
United Therapeutics Corporation (UTHR) reported Equity Method Investment, Realized Gain (Loss) on Disposal of $91.90 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Income Statement › Other Income
us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal · last filed 2022-11-02
- United Therapeutics Corporation equity method investment, realized gain (loss) on disposal for the quarter ending 2021-09-30 was $0.00.
- United Therapeutics Corporation equity method investment, realized gain (loss) on disposal for the quarter ending 2021-06-30 was $0.00.
- United Therapeutics Corporation equity method investment, realized gain (loss) on disposal for the quarter ending 2021-03-31 was $91.90M.
| Period end | Equity Method Investment, Realized Gain (Loss) on Disposal 3 month | Equity Method Investment, Realized Gain (Loss) on Disposal 6 month | Equity Method Investment, Realized Gain (Loss) on Disposal 9 month |
|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $91.90M 10-Q · filed 2022-11-02 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $91.90M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $91.90M 10-Q · filed 2022-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |